BIC-2019

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameBIC-2019
Drug Alias Nameanti-CD19 CAR T-cell therapy (Institute of Hematology & Blood Diseases Hospital)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocytes stimulantsB-lymphocyte antigen CD19 modulatorsImmunostimulants
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesHematology Hospital Of Chinese Academy Of Medical Sciences
China Registration ClassN/A

Develop Information

Active CompaniesHematology Hospital Of Chinese Academy Of Medical Sciences
Inactive CompaniesN/A
Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A